Article
Cell Biology
Artem A. Artykov, Anne Yagolovich, Dmitry A. Dolgikh, Mikhail P. Kirpichnikov, Daria B. Trushina, Marine E. Gasparian
Summary: TRAIL induces apoptosis through DR4 and DR5 on cell surface. Death receptors are rapidly internalized upon ligand stimulation and slowly return to plasma membrane after ligand is eliminated. Inhibition of receptor endocytosis sensitizes resistant cells to TRAIL and increases its cytotoxic activity against sensitive cells.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Cell Biology
Liang Ma, Hong-Ling Wei, Ke-Jie Wang, Xiang-Yu Meng, Sai-Qi Ni, Cheng Zhou, Yi Li, Rui Yu, Qi Ma
Summary: This study found that the combination of rhein (RH) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can inhibit the proliferation and induce apoptosis of bladder cancer cells, suggesting its potential value in clinical treatment.
Article
Biochemistry & Molecular Biology
Yana Vladimirovna Lomovskaya, Margarita Igorevna Kobyakova, Anatoly Sergeevich Senotov, Alexey Igorevich Lomovsky, Vladislav Valentinovich Minaychev, Irina Sergeevna Fadeeva, Daria Yuryevna Shtatnova, Kirill Sergeevich Krasnov, Alena Igorevna Zvyagina, Vladimir Semenovich Akatov, Roman Sergeevich Fadeev
Summary: The resistance of leukemic cells to TRAIL-induced apoptosis is a major challenge in the treatment of leukemia. In this study, researchers discovered that human acute myeloid leukemia cells, when subjected to high-density culture conditions, displayed a macrophage-like phenotype and increased resistance to TRAIL-induced cell death. This resistance can be attributed to a decrease in the expression of death receptors DR4 and DR5 on the leukemic cells. The findings suggest that stress conditions in high-density cell cultures may contribute to tumor progression by promoting TRAIL resistance.
Article
Biochemistry & Molecular Biology
Taiga Seki, Yui Shimizu, Kyota Ishii, Yuzuki Takahama, Kazunori Kato, Tomohiro Yano
Summary: The study showed that NK cells can selectively target androgen-dependent prostate cancer stem-like cells via the TRAIL/DR5 pathway, providing a basis for developing strategies to eliminate prostate cancer stem cells.
Article
Medicine, General & Internal
Joaquin Marco-Brualla, Diego de Miguel, Luis Martinez-Lostao, Alberto Anel
Summary: The resistance of cancer cells to treatments is a significant challenge. However, a new TRAIL formulation called LUV-TRAIL has shown promising results by increasing apoptosis in numerous tumor cell types. Additionally, the metabolic drug DCA has the potential to enhance the sensitivity of cancer cells resistant to LUV-TRAIL, making it a suitable option to overcome TRAIL resistance.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, Research & Experimental
Ya-jun Hou, Dawei Li, Weiqi Wang, Leilei Mao, Xiaoyan Fu, Baoliang Sun, Cundong Fan
Summary: This study evaluated the anticancer effects and mechanism of NT157 against human glioma growth, and found that NT157 alone inhibited glioma cell growth by regulating cell cycle, promoting apoptosis, and inducing DNA damage and dysfunction of signaling pathways. Combined treatment with TRAIL further enhanced apoptosis by upregulating DR5 and inducing DNA damage.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Cell Biology
Ya Lomovskaya, M. Kobyakova, A. S. Senotov, I. S. Fadeeva, A. Lomovsky, K. S. Krasnov, D. Yu Shtatnova, V. S. Akatov, R. S. Fadeev
Summary: The study found that induction of myeloid differentiation in leukemia cells can increase their resistance to TRAIL-induced death, but certain substances can suppress this resistance and improve treatment effectiveness.
BIOLOGICHESKIE MEMBRANY
(2022)
Article
Biochemistry & Molecular Biology
Manami Semba, Shinji Takamatsu, Sachiko Komazawa-Sakon, Eiji Miyoshi, Chiharu Nishiyama, Hiroyasu Nakano, Kenta Moriwaki
Summary: The study identified proscillaridin A as a promising agent that enhances the anti-cancer efficacy of TRAIL therapeutics, particularly in colon cancer cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Anastasia Gileva, Daria Trushina, Anne Yagolovich, Marine Gasparian, Leyli Kurbanova, Ivan Smirnov, Sergey Burov, Elena Markvicheva
Summary: Recently, biodegradable polyelectrolyte multilayer capsules have been proposed for targeted drug delivery of anticancer drugs. In this study, the researchers aimed to develop PMC loaded with a subtoxic concentration of doxorubicin (DOX) and functionalized with the tumor-specific DR5-B ligand to achieve a combined antitumor effect. The effects of PMC surface modification with the DR5-B ligand on cell uptake were studied in both 2D monolayer cultures and 3D tumor spheroids. The results showed that the DR5-B-modified capsules loaded with DOX exhibited enhanced cytotoxicity in both in vitro models, suggesting their potential as a targeted drug delivery system.
Article
Cell Biology
R. S. Fadeev, N. V. Dolgikh, A. V. Chekanov, A. S. Senotov, K. S. Krasnov, M. I. Kobyakova, Ya. V. Lomovskaya, I. S. Fadeeva, V. S. Akatov
Summary: The TNF alpha Related Apoptosis Inducing Ligand (TRAIL) cytokine is of interest for developing targeted antitumor drugs. Previous studies have shown that A-431 cells develop reversible resistance to TRAIL-induced apoptosis under confluent culture conditions. In this study, we found that the increased resistance is associated with reduced expression of pro-apoptotic receptors DR4 and DR5, as well as the absence of anti-apoptotic receptors DcR1 and DcR2 on the cell surface. Decreased representation of DR4 and DR5 receptors is accompanied by a lack of activation of proapoptotic protein Bid and effector caspase 3, leading to increased TRAIL resistance. These findings suggest that the reversible increase in resistance of A-431 cells to TRAIL-induced apoptosis in confluent cultures is caused by a decrease in the expression of DR4 and DR5 receptors on the cell surface.
BIOLOGICHESKIE MEMBRANY
(2023)
Article
Cell Biology
Oliver H. Voss, Daniel Arango, Justin C. Tossey, Miguel A. Villalona Calero, Andrea Doseff
Summary: Apigenin sensitizes primary lung cancer cells to TRAIL-induced apoptosis through reprogramming alternative splicing of key TRAIL/DISC components and directly binding heat shock protein 70 to promote cell death. These findings emphasize the synergies between diet and cancer treatments, providing new avenues for improved cancer therapies.
CELL DEATH & DISEASE
(2021)
Article
Multidisciplinary Sciences
Shima Lotfollahzadeh, Elaheh Sadat Hosseini, Hooman Mahmoudi Aznaveh, Maryam Nikkhah, Saman Hosseinkhani
Summary: This study successfully fabricated a promising nanohybrid system to improve the therapeutic efficacy of TRAIL. By conjugating TRAIL with graphene quantum dots, the study demonstrated enhanced functional stability and effective anticancer activity.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Nagamani Vunnam, Malaney C. Young, Elly E. Liao, Chih Hung Lo, Evan Huber, MaryJane Been, David D. Thomas, Jonathan N. Sachs
Summary: Although nimesulide has been taken off the market due to hepatotoxicity, it is still used as a valuable research tool for developing new anticancer drugs. Several studies have been conducted to modify its structure and develop more potent anticancer agents. Understanding the mechanism of action for nimesulide is crucial in realizing its potential.
CANCER BIOLOGY & THERAPY
(2023)
Article
Oncology
Wenmo Liu, Siqi Wang, Qinchuan Yang, Xinyao Feng, Bin Yu, Xianghui Yu
Summary: 20(s)-ginsenoside Rh2 sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis, enhancing its anti-tumor effect.
Article
Cell Biology
Ya. V. Lomovskaya, M. I. Kobyakova, A. S. Senotov, I. S. Fadeeva, A. I. Lomovsky, K. S. Krasnov, D. Yu. Shtatnova, V. S. Akatov, R. S. Fadeev
Summary: The study revealed that human leukemia cells THP-1, HL-60, and K562 developed resistance to TRAIL-induced death in vitro due to myeloid differentiation induced by exogenous factors, which led to reduced expression of DR4 and DR5 receptors on cell surface. Furthermore, substances such as ONC 201, tunicamycin, and SAHA, which can increase DR5 expression in leukemic cells, were found to suppress TRAIL resistance induced by differentiation factors. These findings are significant for the development of drugs and strategies to improve the treatment of myeloid leukemia.
BIOCHEMISTRY MOSCOW SUPPLEMENT SERIES A-MEMBRANE AND CELL BIOLOGY
(2023)
Article
Oncology
I. C. Kok, J. S. Hooiveld, P. P. van de Donk, D. Giesen, E. L. van der Veen, M. N. Lub-de Hooge, A. H. Brouwers, T. J. N. Hiltermann, A. J. van der Wekken, L. B. M. Hijmering-Kappelle, W. Timens, S. G. Elias, G. A. P. Hospers, H. J. M. Groen, W. Uyterlinde, B. van der Hiel, J. B. Haanen, D. J. A. de Groot, M. Jalving, E. G. E. de Vries
Summary: The study found that the uptake of Zr-89-pembrolizumab in tumor lesions correlated with treatment response and patient survival. The optimal dose was 5 mg pembrolizumab, and the optimal time point for PET scanning was day 7.
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Karlijn de Joode, Jolien Tol, Paul Hamberg, Marissa Cloos, Elisabeth A. Kastelijn, Jessica S. W. Borgers, Veerle J. A. A. Nuij, Yarne Klaver, Gerarda J. M. Herder, Pim G. N. J. Mutsaers, Daphne W. Dumoulin, Esther Oomen-de Hoop, Nico G. J. van Diemen, Eduard J. Libourel, Erica J. Geraedts, Gerben P. Bootsma, Cor H. van der Leest, Anne L. Peerdeman, Karin H. Herbschleb, Otto J. Visser, Haiko J. Bloemendal, Hanneke W. M. van Laarhoven, Elisabeth G. E. de Vries, Lizza E. L. Hendriks, Laurens Beerepoot, Hans M. Westgeest, Franchette W. P. J. van den Berkmortel, John B. A. G. Haanen, Anne-Marie C. Dingemans, Astrid A. M. van der Veldt
Summary: This study aimed to investigate the clinical patient characteristics related to COVID-19 outcomes and advanced care planning in cancer patients. The study found that patients with hematological malignancies or lung cancer were at a higher risk of fatal outcomes compared to other solid tumors, and there was no correlation between anticancer therapies and the risk of fatal COVID-19 outcomes. Timely end-of-life communication and early discussion of treatment restrictions should be part of routine oncological care, especially during the COVID-19 pandemic.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
N. J. Latino, M. Galotti, N. Cherny, E. G. E. de Vries, J-Y Douillard, D. Kaidarova, A. Ilbawi
Summary: The ESMO four-phase approach resulted in updating the Kazakhstan national essential cancer medicines list and cancer treatment protocols, leading to the removal of low-value or non-evidence-based medicines and an increase in budget for cancer care. This approach can improve access to medicines, expenditure efficiency, and sustainability of cancer systems, showcasing how collaboration between WHO and ESMO can positively impact patient care through sharing best practices and resources.
Article
Oncology
Lalitha K. Shankar, Erich Huang, Saskia Litiere, Otto S. Hoekstra, Larry Schwartz, Sandra Collette, Ronald Boellaard, Jan Bogaerts, Lesley Seymour, Elisabeth G. E. deVries
Summary: Currently, guidelines for PET with FDG-PET interpretation for therapy response in oncology involve visual evaluation of FDG-PET/CT scans. However, quantitative measurements of metabolic activity in tumors may be more useful. Guidelines based on such measurements have been proposed, but more analysis is needed for regular use.
CLINICAL CANCER RESEARCH
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Joyce van Sluis, Walter Noordzij, Elisabeth G. E. de Vries, Iris C. Kok, Derk Jan A. de Groot, Mathilde Jalving, Marjolijn N. Lub-de Hooge, Adrienne H. Brouwers, Ronald Boellaard
Summary: This study explores the influence of using manual segmentations versus an AI-based automated segmentation tool on calculating whole-body effective doses. The results show that using AI-based segmentations can save time and achieve higher similarity coefficients compared to manual segmentations. The whole-body effective doses show minimal differences for the six patients.
MOLECULAR IMAGING AND BIOLOGY
(2023)
Review
Public, Environmental & Occupational Health
Kristina Jenei, Zeba Aziz, Christopher Booth, Bernadette Cappello, Francesco Ceppi, Elisabeth G. E. de Vries, Antonio Fojo, Bishal Gyawali, Andre Ilbawi, Dorothy Lombe, Manju Sengar, Richard Sullivan, Dario Trapani, Benedikt D. Huttner, Lorenzo Moja
Summary: The selection of cancer medicines for national procurement requires consideration of various factors, and the WHO has implemented updated processes and selection principles to promote the procurement of high-value essential cancer medicines.
LANCET GLOBAL HEALTH
(2022)
Article
Medicine, General & Internal
Niccolo Rossi, Karla A. Lee, Maria Bermudez, Alessia Visconti, Andrew Maltez Thomas, Laura A. Bolte, Johannes R. Bjork, Laura Kist de Ruijter, Julia Newton-Bishop, Mark Harland, Heather M. Shaw, Mark Harries, Joseph Sacco, Ruth Board, Paul Lorigan, Elisabeth G. E. de Vries, Nicola Segata, Leonie Taams, Sophie Papa, Tim D. Spector, Paul Nathan, Rinse K. Weersma, Geke A. P. Hospers, Rudolf S. N. Fehrmann, Veronique Bataille, Mario Falchi
Summary: This study investigates the potential of circulating inflammatory proteins as biomarkers for immune checkpoint inhibitor therapy in advanced melanoma. The findings suggest that pre-treatment levels of IL-6, HGF, and MCP-2 are associated with treatment response, while on-treatment changes in these proteins are not correlated with response. Inflammatory proteins could serve as predictive biomarkers of ICI response and potential targets for combination therapy.
Article
Oncology
S. F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N. J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E. G. E. de Vries, M. Piccart, N. I. Cherny
Summary: This article discusses the importance of quality of life (QoL) data and quality assurance measures in the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). Through field testing and revision, a checklist consisting of four items was developed to ensure the reliability and clinical relevance of QoL data. Implementation of this checklist will facilitate objective and transparent decision making in the ESMO-MCBS scoring process.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Ramsha Iqbal, Maqsood Yaqub, Huseyyin O. Bektas, Daniela E. Oprea-Lager, Elisabeth G. E. de Vries, Andor W. J. M. Glaudemans, Philippe Aftimos, Geraldine Gebhart, Andrew P. Beelen, Robert C. Schuit, Albert D. Windhorst, Ronald Boellaard, C. Willemien Menke-van der Houven van Oordt
Summary: The purpose of this study was to investigate the use of [18F]-fluorodeoxyglucose ([18F]FDG) and [18F]-fluoro-17(3-estradiol ([18F]FES) PET/CT imaging in patients with metastatic ER-positive breast cancer undergoing treatment with rintodestrant. The study found that absence of ER expression on [18F]FES PET is a predictor for no response to rintodestrant. [18F]FES uptake during treatment and at time of progression is useful to monitor the effect of therapy and continued mode of action of SERDs.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Jahlisa S. Hooiveld-Noeken, Annemarie C. Eggen, Emoke Racz, Elisabeth G. E. de Vries, Anna K. L. Reyners, Mathilde Jalving
Summary: This systematic review explores the potential of immune checkpoint inhibitors (ICIs) in treating advanced non-melanoma skin cancer (NMSC), comparing their effectiveness with melanoma. The study shows that ICIs have comparable response rates in both advanced NMSC and melanoma, and neoadjuvant ICIs have shown promising results in NMSC, with approximately half of the patients achieving complete responses. The authors conclude that neoadjuvant ICI treatment has the potential to avoid mutilating treatments in NMSC, and further progress can be made by learning from melanoma.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Laura Kist de Ruijter, Pim P. van de Donk, Jahlisa S. Hooiveld-Noeken, Danique Giesen, Sjoerd G. Elias, Marjolijn N. Lub-de Hooge, Sjoukje F. Oosting, Mathilde Jalving, Wim Timens, Adrienne H. Brouwers, Thomas C. Kwee, Jourik A. Gietema, Rudolf S. N. Fehrmann, Bernard M. Fine, Sandra M. Sanabria Bohorquez, Mahesh Yadav, Hartmut Koeppen, Jing Jing, Sebastian Guelman, Mark T. Lin, Michael J. Mamounas, Jeffrey Ryan Eastham, Patrick K. Kimes, Simon P. Williams, Alexander Ungewickell, Derk J. A. de Groot, Elisabeth G. E. de Vries
Summary: Immune checkpoint inhibitors (ICIs), by reinvigorating CD8(+) T cell mediated immunity, have revolutionized cancer therapy. However, the systemic distribution and pharmacodynamics of CD8(+) T cells in response to ICIs remains poorly understood. In this study, we used a zirconium-89-labeled, CD8-specific antibody PET tracer to characterize the dynamic distribution of CD8(+) T cells in patients with solid tumors before and after ICI therapy. The results revealed significant heterogeneity in CD8(+) T cell distribution and pharmacodynamics both between and within patients.
Article
Oncology
Marianne Luyendijk, Otto Visser, Hedwig M. Blommestein, Ignace H. J. T. de Hingh, Frank J. P. Hoebers, Agnes Jager, Gabe S. Sonke, Elisabeth G. E. de Vries, Carin A. Uyl-de Groot, Sabine Siesling
Summary: This study evaluated the changes in survival of patients with de novo metastatic solid cancers over the past 30 years. The proportion of M1 disease and net survival rates varied among different cancer types. Better preventive measures and early detection are needed to reduce the incidence of metastatic disease.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Editorial Material
Multidisciplinary Sciences
Elena Garralda, Scott A. Laurie, Lesley Seymour, Elisabeth G. E. de Vries
Summary: Early detection of immunotherapy-induced tumor response is crucial, but therapy-induced pseudoprogression can make it complicated. A consensus guideline called iRECIST, a modification of RECIST version 1.1, was developed. This article explores the next steps required to test its validity and proposes novel approaches for response criteria.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Elisabeth G. E. de Vries, Josef Rueschoff, Martijn Lolkema, Josep Tabernero, Luca Gianni, Emile Voest, Derk Jan A. de Groot, Daniel Castellano, Gilles Erb, Julia Naab, Margarita Donica, Regula Deurloo, Michiel S. van Der Heijden, Giuseppe Viale
Summary: This study aimed to investigate tumor HER2 expression and its effects on T-DM1 treatment in patients with HER2-positive urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. The results showed that some HER2-positive bladder cancer and pancreatic cancer patients responded well to T-DM1, and it also provided insight into the prevalence of HER2 positivity and expression patterns in these three non-breast tumor types.
Article
Oncology
Manju Sengar, Adam Fundytus, Wilma Hopman, C. S. Pramesh, Venkatraman Radhakrishnan, Prasanth Ganesan, Aju Mathew, Dorothy Lombe, Matthew Jalink, Bishal Gyawali, Dario Trapani, Felipe Roitberg, Elisabeth G. E. De Vries, Lorenzo Moja, Andre Ilbawi, Richard Sullivan, Christopher M. Booth
Summary: This study evaluated the highest priority drugs identified by Indian oncologists and their availability in routine practice. The results showed that the most commonly selected drugs were conventional cytotoxic drugs, but access to these treatments was limited by significant financial burdens experienced by patients, especially within the private health system.
JCO GLOBAL ONCOLOGY
(2022)